Format

Send to

Choose Destination
Biochem Pharmacol. 2008 May 15;75(10):1981-93. doi: 10.1016/j.bcp.2008.02.019. Epub 2008 Feb 26.

Akt activation protects pancreatic beta cells from AMPK-mediated death through stimulation of mTOR.

Author information

1
Diabetes Research Center, Brussels Free University, VUB, Partner of the Juvenile Diabetes Research Center for Beta Cell Therapy in Europe, Laarbeeklaan 103, B-1090 Brussels, Belgium.

Abstract

Sustained activation of AMP-activated protein kinase (AMPK) induces apoptosis in several cell types. In pancreatic beta cells this occurs under glucose limitation, or in the presence of the pharmacological AMPK activator 5-aminoimidazole-4-carboxamide-riboside (AICAR). It is unknown whether Akt activation can counteract AMPK-mediated apoptosis, nor whether mTOR activation downstream of Akt mediates any survival signal in these conditions. We report that expression of a constitutively active form of Akt increases mTOR activity and prevents apoptosis upon AMPK activation. Akt-mediated survival was inhibited by rapamycin. Expression of a constitutively active form of the mTOR target ribosomal protein S6 kinase (S6K) or of translation factor eIF4E reduced apoptosis by glucose limitation, and co-expression of S6K and eIF4E protected beta cells to the same extent as active Akt. The protective effects of active Akt and S6K were associated with increased cellular protein synthesis activity. It is concluded that Akt stimulation of mTOR and subsequent activation of the targets by which mTOR affects protein translation are required and sufficient mechanisms for Akt-mediated survival of beta cells undergoing sustained AMPK activation.

PMID:
18377870
DOI:
10.1016/j.bcp.2008.02.019
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center